Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31123833 | 1.00 | BACE1 (0.42) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL8155187 | 0.83 | BACE1 (0.42) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL30908183 | 0.79 | KMT2A (0.54) | HTTCYP1A2PABPC1KMT2ANPSR1 | |
| SCHEMBL30002881 | 0.79 | BACE1 (0.50) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL21682209 | 0.79 | BACE1 (0.50) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL18571554 | 0.77 | BACE1 (0.46) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL2178320 | 0.77 | EGFR (0.53) | HTTEGFRTOP2ATOP2BKMT2A | |
| SCHEMBL30159323 | 0.77 | BACE1 (0.46) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL18571738 | 0.76 | BACE1 (0.48) | BACE1HTTCYP1A2CYP2C19PABPC1 | |
| SCHEMBL3614209 | 0.73 | BACE1 (0.46) | BACE1HTTCYP1A2CYP2C19PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833668-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12173026-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-11993602-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-05-28 | — | — | US | disclosed |
| US-20230062119-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME LLC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20220363707-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20210277009-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-09-09 | — | — | US | disclosed |
| WO-2021126999-A1 | USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3833355-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3833668-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112805006-A | PRMT5 inhibitor | 默沙东公司 | 2021-05-14 | — | — | CN | disclosed |
| WO-2020033288-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033288-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033282-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363707-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | BACE1 2546/4885HTT 1172/4885CYP1A2 1814/4885 |
| US-12173026-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | BACE1 2546/4885HTT 1172/4885CYP1A2 1814/4885 |
| US-11993602-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | BACE1 1740/4885HTT 3831/4885CYP1A2 2495/4885 |
| US-20210277009-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | BACE1 1740/4885HTT 3831/4885CYP1A2 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.